| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OPCML |
| Uniprot No | Q14982-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-322aa |
| 氨基酸序列 | MGVCGYLFLP WKCLVVVSLR LLFLVPTGVP VRSGDATFPK AMDNVTVRQG ESATLRCTID DRVTRVAWLN RSTILYAGND KWSIDPRVII LVNTPTQYSI MIQNVDVYDE GPYTCSVQTD NHPKTSRVHL IVQVPPQIMN ISSDITVNEG SSVTLLCLAI GRPEPTVTWR HLSVKEGQGF VSEDEYLEIS DIKRDQSGEY ECSALNDVAA PDVRKVKITV NYPPYISKAK NTGVSVGQKG ILSCEASAVP MAEFQWFKEE TRLATGLDGM RIENKGRMST LTFFNVSEKD YGNYTCVATN KLGNTNASIT LYGPGAVIDG VN |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OPCML重组蛋白的3篇参考文献示例(文献信息为模拟内容，供参考)：
---
1. **文献名称**: *"Cloning and expression of OPCML recombinant protein in mammalian cells: a tumor suppressor role in epithelial cancers"*
**作者**: Sastry, K. et al.
**摘要**: 研究团队成功克隆并表达了人源OPCML基因的重组蛋白，验证其在HEK293细胞中的分泌表达。实验表明，重组OPCML蛋白能显著抑制卵巢癌细胞系的增殖和迁移，并通过调控EGFR信号通路发挥肿瘤抑制作用。
---
2. **文献名称**: *"Structural and functional characterization of recombinant OPCML reveals its role in cell adhesion via glycosylation modification"*
**作者**: Chen, L. et al.
**摘要**: 通过大肠杆菌和昆虫细胞系统表达纯化OPCML重组蛋白，分析其糖基化修饰对功能的影响。研究发现，糖基化OPCML可增强细胞间黏附，并抑制肺癌细胞的侵袭能力，提示其作为细胞外基质调控因子的潜在机制。
---
3. **文献名称**: *"OPCML recombinant protein synergizes with cisplatin to induce apoptosis in gastric cancer through epigenetic modulation"*
**作者**: Zhang, Y. et al.
**摘要**: 研究利用原核表达系统获得高纯度OPCML重组蛋白，发现其能增强胃癌细胞对顺铂的敏感性。机制研究表明，OPCML通过去甲基化作用恢复抑癌基因表达，并激活线粒体凋亡通路，为联合化疗提供新策略。
---
**备注**：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索真实文献。
OPCML (Opioid Binding Protein/Cell Adhesion Molecule-Like) is a member of the IgLON family of cell adhesion molecules, initially identified for its structural homology to opioid-binding proteins. It is encoded by the OPCML gene located on human chromosome 11q25. Functionally, OPCML plays a critical role in cell-cell adhesion, signal transduction, and tumor suppression. Its involvement in cancer biology has been extensively studied, as OPCML is frequently epigenetically silenced through promoter hypermethylation in various malignancies, including ovarian, lung, and hepatocellular cancers. This silencing correlates with tumor progression, metastasis, and poor prognosis, highlighting its role as a putative tumor suppressor.
Recombinant OPCML protein is engineered to mimic the native protein’s structure and function, typically produced using expression systems like *E. coli* or mammalian cells. The protein consists of three immunoglobulin-like (Ig-like) domains and a glycosylphosphatidylinositol (GPI) anchor site, which mediates its attachment to cell membranes. Recombinant forms often exclude the GPI anchor for solubility, enabling *in vitro* studies. Researchers use it to investigate OPCML’s tumor-suppressive mechanisms, such as inhibiting proliferation, migration, and invasion of cancer cells by modulating receptor tyrosine kinases (e.g., EGFR, HER2) or downstream pathways like MAPK/ERK.
Its therapeutic potential is being explored, including gene therapy or recombinant protein delivery to restore OPCML function in cancers. Additionally, OPCML’s role in neural development and synaptic plasticity is an emerging area, though less characterized. Challenges include optimizing bioavailability and tissue targeting. Overall, recombinant OPCML serves as a vital tool for dissecting its biological roles and translational applications in oncology and beyond.
×
